Guillain-Barré Syndrome After Receiving the First Dose of Oxford–AstraZeneca SARS-CoV-2 Vaccine

Guillain-Barré Syndrome After Receiving the First Dose of Oxford–AstraZeneca SARS-CoV-2 Vaccine

Safety monitoring of COVID-19 vaccination is paramount of importance. There are limited reports of Guillain-Barré syndrome (GBS) associated with the COVID-19 vaccination. The present study reported a case of GBS following the first dose of the Oxford-AstraZeneca SARS-CoV-2 vaccine. A 32-year-old ma...

Full description

Bibliographic Details
Main Authors:	Hossein Mozhdehipanah, Shirin Mavandadi, Sepideh Paybast
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2022-07-01
Series:	Acta Medica Iranica
Subjects:	Coronavirus disease 2019 (COIVD-19) vaccine Oxford–AstraZeneca vaccine Guillain-Barré syndrome
Online Access:	https://acta.tums.ac.ir/index.php/acta/article/view/9596

Similar Items

Miller–Fisher syndrome after first dose of Oxford/AstraZeneca coronavirus disease 2019 vaccine: a case report
by: Fernanda Junqueira Cesar Pirola, et al.
Published: (2022-11-01)

ANCA-associated vasculitis following Oxford-AstraZeneca COVID-19 vaccine in Brazil: Is there a causal relationship? A case report
by: Welder Zamoner, et al.
Published: (2022-10-01)

Side Effects Following Administration of the First Dose of Oxford-AstraZeneca’s Covishield Vaccine in Bangladesh: A Cross-Sectional Study
by: Nishat Jahan, et al.
Published: (2021-10-01)

Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
by: Waleed H. Mahallawi, et al.
Published: (2021-12-01)

A Battle against COVID-19: Vaccine Hesitancy and Awareness with a Comparative Study between Sinopharm and AstraZeneca
by: Marian S. Boshra, et al.
Published: (2022-02-01)

Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study
by: Elias Ali Yesuf, et al.
Published: (2022-07-01)

Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand
by: Uraporn Phumisantiphong, et al.
Published: (2023-04-01)

Cross-Reactivity between Half Doses of Pfizer and AstraZeneca Vaccines—A Preliminary Study
by: Krzysztof Lukaszuk, et al.
Published: (2022-03-01)

Crisis Communication during COVID-19: English, French, Portuguese, and Spanish Discourse of AstraZeneca Vaccine and Omicron Variant on Social Media
by: Daniel Catalan-Matamoros, et al.
Published: (2023-06-01)

Local myofascitis of the deltoid muscle after administration of the AstraZeneca (AZD1222) COVID-19 vaccine: two cases, infectious and inflammatory
by: Jong Pil Yoon, MD, et al.
Published: (2022-08-01)

Delayed Cutaneous Adverse Reaction of the AstraZeneca COVID-19 Vaccine in a Breastfed Female Infant: A Coincidence or a Rare Effect?
by: Patrícia Diogo, et al.
Published: (2022-04-01)

Paroxysmal supra-ventricular ventricular tachycardia after AstraZeneca COVID-19 vaccine injection
by: Y.-T. Lin, et al.
Published: (2022-01-01)

Concomitant myocarditis and painless thyroiditis after AstraZeneca coronavirus disease 2019 vaccination: a case report
by: Apichai Marsukjai, et al.
Published: (2022-05-01)

A prospective cohort study protocol: monitoring and surveillance of adverse events following heterologous booster doses of Oxford AstraZeneca COVID-19 vaccine in previous recipients of two doses of Sinopharm or Sputnik V vaccines in Iran
by: Shahin Soltani, et al.
Published: (2023-07-01)

Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety
by: Marek Mikołajczyk, et al.
Published: (2022-12-01)

Thrombocytopenia and Intracranial Venous Sinus Thrombosis after “COVID-19 Vaccine AstraZeneca” Exposure
by: Marc E. Wolf, et al.
Published: (2021-04-01)

Myocarditis following AstraZeneca (an adenovirus vector vaccine) COVID‐19 vaccination: A case report
by: Shakiba Hassanzadeh, et al.
Published: (2022-04-01)

Cerebral venous sinus thrombosis following intracerebral hemorrhage after COVID‐19 AstraZeneca vaccination: A case report
by: Arsh Haj Mohamad Ebrahim Ketabforoush, et al.
Published: (2022-11-01)

Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review
by: Lia Reynolds, et al.
Published: (2023-10-01)

Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm
by: Enayat Anvari, et al.
Published: (2022-09-01)

AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2
by: Marah G. Chibwana, et al.
Published: (2022-03-01)

Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy
by: Jennifer Serwanga, et al.
Published: (2023-05-01)

Evaluation and comparison of post-vaccination adverse effects among Janssen and Oxford-AstraZeneca vaccinated adult individuals in Debre Tabor Town: A cross- sectional survey in Northwest Ethiopia
by: Endeshaw Chekol Abebe, et al.
Published: (2022-11-01)

AstraZeneca COVID‐19 vaccine: A possible risk factor for ischemic stroke and cerebral venous sagittal sinus thrombosis: A case series
by: Amira Siddig, et al.
Published: (2022-07-01)

Adverse reactions following COVID-19 vaccine among healthcare professionals working in Ethiopia: a facility-based cross-sectional study
by: Adisu Asefa, et al.
Published: (2023-11-01)

An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam
by: Nguyen Van Vinh Chau, et al.
Published: (2021-11-01)

End-Stage Kidney Disease Resulting from Atypical Hemolytic Uremic Syndrome after Receiving AstraZeneca SARS-CoV-2 Vaccine: A Case Report
by: Mohammed Tawhari, et al.
Published: (2023-03-01)

An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines
by: Suhaila A. Al-Sheboul, et al.
Published: (2022-12-01)

Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study
by: Jehad Aldali, et al.
Published: (2023-01-01)

Adverse effects of Oxford-AstraZeneca COVID-19 vaccine among Egyptian healthcare workers
by: Mai Al Kaffas, et al.
Published: (2022-10-01)

Surveillance of COVID-19 vaccines: A comprehensive analysis of the first immunization drive in Ecuador
by: Andrea Orellana-Manzano, et al.
Published: (2024-03-01)

Prevalence of COVID‐19 vaccine reactogenicity among Bangladeshi physicians
by: Md. Anwarul Azim Majumder, et al.
Published: (2022-06-01)

The first report of myocarditis followed by AstraZeneca vaccination in Iran
by: Karo Servatyari, et al.
Published: (2022-06-01)

Antibody Response to Sars-CoV-2 in Adults After 18 Months of Second Dose Vaccination of Astra Zeneca
by: Handayani Sarwo, et al.
Published: (2024-01-01)

Relapse of immune thrombocytopenia after receiving AstraZeneca coronavirus disease‐2019 vaccine: A case report
by: Saba Seyedi, et al.
Published: (2023-09-01)

EVENTOS ADVERSOS À 3ª DOSE DAS VACINAS ASTRAZENECA E PFIZER EM UMA COORTE DE TRABALHADORES DA SAÚDE
by: Maria da Penha Gomes Gouvea, et al.
Published: (2023-10-01)

Post COVID-19 vaccination Guillain-Barre syndrome: three cases
by: Seyedehnarges Tabatabaee, et al.
Published: (2022-11-01)

Surveillance of Post-Vaccination Side Effects of COVID-19 Vaccines among Saudi Population: A Real-World Estimation of Safety Profile
by: Abdulaziz Ibrahim Alzarea, et al.
Published: (2022-06-01)

Pre-Vaccination Stress, Post-Vaccination Adverse Reactions, and Attitudes towards Vaccination after Receiving the COVID-19 Vaccine among Health Care Workers
by: Sylwia Kałucka, et al.
Published: (2022-03-01)

"Sinopharm", "Oxford-AstraZeneca", and "Pfizer-BioNTech" COVID-19 vaccinations: testing efficacy using lung CT-volumetry with comparative analysis of variance (ANOVA)
by: Ahmed Samir, et al.
Published: (2023-03-01)